TBPH Q3 2022 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-5.6% YoY

Gross Profit

$3M20.8% margin

Operating Income

-$14M-114.1% margin

Net Income

$917M7361.9% margin

EPS (Diluted)

$12.14

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$763M

Total Liabilities

$283M

Stockholders' Equity

$481M

Cash & Equivalents

$419M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-5.6%
Gross Profit	$3M	-$31M	+108.5%
Operating Income	-$14M	-$54M	+73.5%
Net Income	$917M	-$35M	+2696.1%

Revenue Segments

YUPELRI Monotherapy

$19M60%

Viatris collaboration agreement

$12M40%

Collaboration revenue

$6,0000%